nach oben

Neurological Sciences

Erschienen in:

05.02.2021 | Original Article

Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study

verfasst von: Maria Michela Cainazzo, Carlo Baraldi, Anna Ferrari, Flavia Lo Castro, Luca Pani, Simona Guerzoni

Erschienen in: Neurological Sciences | Ausgabe 10/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Erenumab is a monoclonal antibody blocking the calcitonin gene–related peptide receptor, which has been approved for the preventive treatment of chronic migraine (CM). The aim of this study was to explore the safety and effectiveness of erenumab in patients suffering from CM and medication overuse headache (MOH) in a real-life setting, up to 1 year.

Methods

Data regarding 81 patients treated with erenumab were retrospectively analyzed. Every 3 months, the following variables were collected: the mean number of headache days per month (headache index (HI)), the average number of painkillers taken per month (analgesic consumption (AC)), the mean number of days with painkiller consumption (number of days on medication (NDM)), the headache intensity (numeric rating scale (NRS) score), the 6-item Headache Impact Test (HIT-6), and the Self-Reported Instrument to Assess Work-Related Difficulties in Patients With Migraine (HEADWORK) scores.

Results

The HI, AC, and NDM and the NRS, HIT-6, and HEADWORK scores were significantly lower at every time point from the 3rd month onward compared to baseline (all P < 0.0001). No significant differences were found between patients who underwent painkiller detoxification before starting erenumab and those who did not (all P > 0.05). No significant differences were found between patients taking erenumab in combination with other preventive treatments and the ones taking it alone (all P ≥ 0.05). Five patients dropped out because of adverse events, which resolved after stopping erenumab.

Conclusion

Erenumab was safe and effective for CM complicated with MOH. Painkiller withdrawal and the association with other preventive treatment(s) seem useless.

Nur mit Berechtigung zugänglich

Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38:1–211. https://doi.org/10.1177/0333102417738202CrossRef

Diener HC, Holle D, Solbach K, Gaul C (2016) Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol 12:575–583. https://doi.org/10.1038/nrneurol.2016.124CrossRefPubMed

Buse DC, Manack AN, Fanning KM, Serrano D, Reed ML, Turkel CC, Lipton RB (2012) Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache 52:1456–1470. https://doi.org/10.1111/j.1526-4610.2012.02223.xCrossRefPubMed

Lanteri-Minet (2014) Economic burden and costs of chronic migraine. Curr Pain Headache Rep 18:358. https://doi.org/10.1007/s11916-013-0385-0CrossRef

Carlsen LN, Munksgaard SB, Jensen RH, Bendtsen L (2018) Complete detoxification is the most effective treatment of medication- overuse headache: a randomized controlled open-label trial. Cephalalgia 38:225–236. https://doi.org/10.1177/0333102417737779CrossRefPubMed

Steiner TJ, Jensen R, Katsarava Z, Linde M, MacGregor EA, Osipova V, Paemeleire K, Olesen J, Peters M, Martelletti P (2019) Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting The Burden: The Global Campaign Against Headache. J Headache Pain 20:57. https://doi.org/10.1186/s10194-018-0899-2CrossRefPubMedPubMedCentral

Markham A (2018) Erenumab: first global approval. Drugs 78:1157–1161. https://doi.org/10.1007/s40265-018-0944-0CrossRefPubMed

Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein SD, Winner P, Leonardi D, Mikol D, Lenz R (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16:425–434. https://doi.org/10.1016/S1474-4422(17)30083-2CrossRefPubMed

Tepper SJ, Diener HC, Ashina M, Brandes JL, Friedman DI, Reuter U, Cheng S, Nilsen J, Leonardi DK, Lenz RA, Mikol DD (2019) Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. Neurology 92:20–e2320. https://doi.org/10.1212/WNL.0000000000007497CrossRef

10.

Schiano Di Cola F, Rao R, Caratozzolo S, Di Cesare M, Venturelli E, Balducci U, Sidoti V, Pari E, Costanzi C, Di Summa A, Sixt GJ, D’Adda E, Liberini P, Padovani A Erenumab efficacy in chronic migraine and medication overuse: a real-life multicentric Italian observational study. Neurol Sci 41:489–490

11.

Curone M, Tullo V, Bussone G (2020) Effectiveness of erenumab in chronic migraine patients with associated medication overuse headache: a prospective observational study. Neurol Sci 41:509–510. https://doi.org/10.1007/s10072-020-04690-1CrossRefPubMed

12.

Ashina M, Tepper S, Brandes JL, Reuter U, Boudreau G, Dolezil D, Cheng S, Zhang F, Lenz R, Klatt J, Mikol DD (2018) Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia 38:1611–1621. https://doi.org/10.1177/0333102418788347CrossRefPubMed

13.

Lipton RB, Tepper SJ, Reuter U, Silberstein S, Stewart WF, Nilsen J, Leonardi DK, Desai P, Cheng S, Mikol DD, Lenz R (2019) Erenumab in chronic migraine: patient-reported outcomes in a randomized double-blind study. Neurology 92:19–e2260. https://doi.org/10.1212/WNL.0000000000007452CrossRef

14.

Sussman M, Benner J, Neumann P, Menzin J (2018) Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: results from the US societal and payer perspectives. Cephalalgia 38:1644–1657. https://doi.org/10.1177/0333102418796842CrossRefPubMed

15.

Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, Martelletti P (2019) European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 20:6. https://doi.org/10.1186/s10194-018-0955-yCrossRefPubMedPubMedCentral

16.

Yang M, Rendas-Baum R, Varon SF, Kosinski M (2011) Validation of the Headache Impact Test (HIT-6) across episodic and chronic migraine. Cephalalgia 31:357–367. https://doi.org/10.1177/0333102410379890CrossRefPubMedPubMedCentral

17.

Raggi A, Covelli V, Guastafierro E, Leonardi M, Scaratti C, Grazzi L, Bartolini M, Viticchi G, Cevoli S, Pierangeli G, Tedeschi G, Russo A, Barbanti P, Aurilia C, Lovati C, Giani L, Frediani F, Di Fiore P, Bono F, Rapisarda L, D’Amico D (2018) Validation of a self-reported instrument to assess work-related difficulties in patients with migraine: the HEADWORK questionnaire. J Headache Pain 19:85. https://doi.org/10.1186/s10194-018-0914-7CrossRefPubMedPubMedCentral

18.

Tepper SJ, Ashina M, Reuter U, Brandes JL, Dolezil D, Silberstein SD, Winner P, Zhnag F, Cheng S, Mikol DD (2020) Long-term safety and efficacy of erenumab in patients with chronic migraine: results from a 52-week, open-label extension study. Cephalalgia 40:543–453. https://doi.org/10.1177/0333102420912726CrossRefPubMed

19.

Raffaelli B, Kalantzis R, Mecklenburg J, Hendrik Overeem L, Neeb L, Gendolla A, Reuter U (2020) Erenumab in chronic migraine patients who previously failed five first-line oral prophylactics and onabotulinumtoxinA: a dual-center retrospective observational study. Front Neurol 1:417. https://doi.org/10.3389/fneur.2020.00417CrossRef

20.

Garces F, Mohr C, Zhang L, Huang CS, Chen Q, King C, Xu C, Wang Z (2020) Molecular insight into recognition of the CGRPR complex by migraine prevention therapy Aimovig (erenumab). Cell Rep 30:1714–1723. https://doi.org/10.1016/jcelrep.2020.01.029

21.

Wan D, Hou L, Zhang X, Han X, Chen M, Tang W, Liu R, Dong Z, Yu S (2015) DNA methylation of RAMP1 gene in migraine: an exploratory analysis. J Headache Pain 16:90. https://doi.org/10.1186/s10194-015-0576-7CrossRefPubMedPubMedCentral

22.

Scheffler A, Messel O, Wurthmann S, Nsaka M, Kleinschnitz C, Glas M, Naegel S, Holle D (2020) Erenumab in highly therapy-refractory migraine patients: first German real-world evidence. J Headache Pain 21:84. https://doi.org/10.1186/s10194-020-01151-0CrossRefPubMedPubMedCentral

23.

Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB (2015) Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 35:478–488. https://doi.org/10.1177/0333102414547138CrossRefPubMed

24.

Lambru G, Hill B, Murphy M, Tylova I, Andreou AP (2020) A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 21:61. https://doi.org/10.1186/s10194-020-01127-0CrossRefPubMedPubMedCentral

25.

Houts CR, Wirth RJ, McGinley JS, Cady R, Lipton RB (2020) Determining thresholds for meaningful change for the headache impact test (HIT-6) total and item-specific scores in chronic migraine. Headache 60:2003–2013. https://doi.org/10.1111/7head.13946CrossRefPubMedPubMedCentral

26.

Yang M, Rendas-Baum R, Varon SF, Kosinski M (2011) Validation of the headache impact test (HIT-6^TM) across episodic and chronic migraine. Cephalalgia 31:357–367. https://doi.org/10.1177/0333102410379890CrossRefPubMedPubMedCentral

27.

Lanteri-Minet M, Duru G, Mudge M, Cottrell S (2011) Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia 31:837–850. https://doi.org/10.1177/0333102411398400CrossRefPubMed

28.

Pompili M, Di Cosimo D, Innamorati M, Lester D, Tatarelli R, Martelletti P (2009) Psychiatric comorbidity in patients with chronic daily headache and migraine: a selective overview including personality traits and suicide risk. J Headache Pain 10:283–290. https://doi.org/10.1007/s10194-009-0134-2CrossRefPubMedPubMedCentral

29.

Teixeira AL, Coelho Costa EA, Albero da Silva A, Moreira dos Santos IA, Gomez RS, Kummer A, Lautherbach EC (2012) Psychiatric comorbidities of chronic migraine in community and tertiary care clinic samples. J Headache Pain 13:551–555. https://doi.org/10.1007/s10194-012-0480-3CrossRefPubMedPubMedCentral

30.

Seddik AH, Branner JC, Ostwald DA, Schramm SH, Bierbaum M, Katsarava Z (2020) The socioeconomic burden of migraine: an evaluation of productivity losses due to migraine headache based on a population study in Germany. Cephalalgia 40:1551–1560. https://doi.org/10.1177/0333102420944842CrossRefPubMed

31.

Peterlin BL, Calhoun AH, Siegel S, Mathew NT (2008) Rational combination therapy in refractory migraine. Headache 48:805–819. https://doi.org/10.1111/j1526-4610.2008.01142.xCrossRefPubMed

32.

Hepp Z, Bloudek LM, Varon SF (2014) Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm 20:22–33. https://doi.org/10.18553/jmcp.2014.20.1.22CrossRefPubMed

33.

Carlsen LN, Munksgaard SB, Jensen RH, Bendtsen L (2017) Complete detoxification is the most effective treatment of medication overuse-headache: a randomized controlled open-label trial. 38:225–236. https://doi.org/10.1177/0333102417737779

34.

Rossi P, Faraoni JV, Nappi G (2009) Medication overuse headache: predictors and rate of relapse in migraine patients with low medical needs. A 1-year prospective study. Cephalalgia 28:1196–1200. https://doi.org/10.1111/j.1468-2982.2008.01659.xCrossRef

35.

Ornello R, Tiseo C, Frattale I, Perrotta G, Marini C, Pistoia F, Sacco S (2019) The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal. J Headache Pain 20:99. https://doi.org/10.1186/s10194-019-1054-4CrossRefPubMedPubMedCentral

36.

Rothrock JF, Manack Adams A, Lipton RB, Silberstein RB, Jo E, Zhao X, Blumenfeld AM, FORWARD Study investigative group (2019) FORWARD study: evaluating the comparative effectiveness of onabotulinumtoxinA and topiramate for headache prevention in adults with chronic migraine. Headache 59:1700–1713. https://doi.org/10.1111/head.13653CrossRefPubMedPubMedCentral

37.

Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA, Assetta M, Maddestra M, Marzoli F, Viola S, Cerone D, Marini C, Pistoia F, Sacco S (2020) Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain 21:32. https://doi.org/10.1186/s10194-020-01102-9CrossRefPubMedPubMedCentral

38.

Falkenberg K, Ronde Bjerg H, Olesen J (2020) Two-hour CGRP infusion causes gastrointestinal hyperactivity: possible relevance for CGRP antibody treatment. Headache 60:929–937. https://doi.org/10.1111/head.13795CrossRefPubMed

39.

Brandes JL, Diener HC, Dolezil D, Freeman MC, McAllister PJ, Winner P, Klatt J, Cheng S, Zhang F, Wen S, Ritter S, Lenz RA, Mikol DD (2020) The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response. Cephalalgia 40:28–38. https://doi.org/10.1177/0333102419894559CrossRefPubMed

Titel: Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study
verfasst von: Maria Michela Cainazzo
Carlo Baraldi
Anna Ferrari
Flavia Lo Castro
Luca Pani
Simona Guerzoni
Publikationsdatum: 05.02.2021
Verlag: Springer International Publishing
Erschienen in: Neurological Sciences / Ausgabe 10/2021
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-021-05105-5

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Vierten reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2021

Small-expanded allele spinocerebellar ataxia 17: imaging and phenotypic variability

MR spectroscopy and imaging-derived measurements in the supplementary motor area for biomarkers of amyotrophic lateral sclerosis

Chemotherapy and peripheral neuropathy

Can diplopia complaint be reduced by telerehabilitation in multiple sclerosis patient during the pandemic?: A case report

Zonisamide in Parkinson’s disease: a current update